SPECIAL

Referenzen

Cornford P et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Eur Urol. 2017 Apr;71(4):630-642.
Cathomas R et al. Das Prostatakarzinom im Wandel. Grundpfeiler der Diagnostik, Behandlung und Interdisziplinarität. Schweiz Med Forum. 2011;11(43):759–63.
Buttigliero C et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat. Rev. 2015;41(10):884–92.
Karantanos T et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 2015;67(3):470–9.
Antonarakis ES et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015;1(5):582–91.
Onstenk W et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur. Urol. 2015;68(6):939–45.
Robinson D et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–28.
Sandhu SK et al. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2013;24(5):1416–8.
Padhani AR et al. Rationale for Modernising Imaging in Advanced Prostate Cancer. Eur. Urol. Focus. in press.
Perez-Lopez R et al. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2017 Apr;283(1):168-177.
Miller K et al. Metastasiertes kastrations-resistentes Prostatakarzinom - Aktuelle Daten, neue Therapieoptionen und strukturiertes Therapie-monitoring. Urol. Ausg A. 2016;55(9):1206–12.
Maines F et al. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit. Rev. Oncol. Hematol. 2015;96(3):498–506.
Sonpavde G et al. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. Clin. Genitourin. Cancer. 2015;13(4):309–18.
Caffo O et al. Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study. Ann. Oncol. 2016;27(Suppl 6, Abstr. 743P).
Gschwend JE et al. Trials in progress: SCOPE – an international, prospective, non-interventional trial to evaluate the influence of the therapy sequence in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Cabazitaxel. Oncol Res Treat. 2016;39(Suppl 1, Abstr. ID0210).
Pritchard CC et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N. Engl. J. Med. 2016;375(5):443–53.
Mateo J et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N. Engl. J. Med. 2015;373(18):1697–708.
Scher HI et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. JAMA Oncol. 2016;2(11):1441–9.
Scher HI et al. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer. Eur. Urol. 2017;71(6):874-882
Han D et al. A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget. 2017;8(4):6796–808.
Mateo J et al. DNA Repair in Prostate Cancer: Biology and Clinical Implications. Eur. Urol. 2017;71(3):417–25.
de Leeuw R et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2015;21(4):795–807.
Le DT et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015;372(26):2509–20.
Dominguez-Valentin M et al. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol. 2016;16:15.
Padhani AR et al. METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur. Urol. 2017;71(1):81–92.
Bryce AH et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017;in press.
Maurer T et al. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 2016;13(4):226–35.
Perera M et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. 2016;70(6):926–37.
Robertson NL et al. Combined whole-body and multi-parametric prostate MRI as a single-step approach for the simultaneous assessment of local recurrence and metastatic disease after radical prostatectomy. J. Urol. 2017;S0022-5347(17)30292-6.
Loriot Y et al. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
Cancer. 2017;123(2):253–62.
Goodman OB et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(1):34–9.

Weitere Informationen entnehmen Sie bitte der Fachinformation auf www.swissmedicinfo.ch.

a Tour d’Europe, Institute of Cancer Research (ICR) and Royal Marsden NHS Foundation Trust, 1–2 Dezember 2016, London, Sponsor: Sanofi Genzyme

b AR-V7: Androgenrezeptor-Variante 7

c ATM: Ataxia teleangiectasia mutated

d BRCA: Breast Cancer

e PARP: Poly-ADP-Ribose-Polymerase

f tDV: total Diffusion Volume

g ADC: Apparent Diffusion Coefficient

Impressum

Redaktion:
H+O communications Ltd.
www.hando.ch

Unterstützt von Sanofi Genzyme

Kontakt:
Sanofi Genzyme,
Gulmmatt,
6340 Baar.

SACH.CAB.17.04.0220

31 March 2017